Revenue guidance

In its fiscal 2019 fourth-quarter earnings investor presentation, Medtronic (MDT) guided for YoY (year-over-year) organic revenue growth of +/- 4% for fiscal 2020. Assuming constant foreign exchange rates, the company has estimated a negative YoY revenue impact of 1.0%–1.5% for fiscal 2020. Based on these revenue growth projections, the company has guided for revenue in the range of +/- $31.3 billion–$31.5 billion for fiscal 2020.

On its fourth-quarter earnings conference call, Medtronic guided for YoY organic revenue growth of 2%–2.5% and a negative revenue impact due to foreign exchange at a current rate of 2.1%–2.6% in the first quarter of fiscal 2020. Medtronic expects to report lower-than-normal sequential revenue growth in the first quarter of fiscal 2020. According to its fourth-quarter earnings conference call, this projection is partly based on its stronger-than-expected revenue performance in the fourth quarter of fiscal 2019 and the ongoing uncertainty associated with paclitaxel-coated balloons in its peripheral business.

Medtronic Has Guided for a Modest Revenue Performance in 2020

Further, temporary challenges associated with the shutdown of a facility of one of Medtronic’s minimally invasive therapies group business’s key sterilization suppliers is also expected to have a detrimental impact on the company’s first-quarter revenue performance. To learn more about the regulatory challenges faced by Medtronic’s paclitaxel-coated balloons business, read A Look at Boston Scientific’s Gross Margin in 2019.

Wall Street estimates

Medtronic reported revenue of $30.56 billion, a YoY rise of 5.5% on an organic basis, ahead of the guidance of 4.0%–4.5% it provided for fiscal 2019.

Analysts expect Medtronic’s revenue to see YoY rises of 3.04% to $31.49 billion in fiscal 2020, 4.63% to $32.94 billion in fiscal 2021, and 4.94% to $34.57 billion in fiscal 2022.

Analysts also expect Medtronic’s revenue to see YoY rises of 0.27% to $7.40 billion in the first quarter, 2.23% to $7.65 billion in the second quarter, 3.81% to $7.83 billion in the third quarter, and 4.69% to $8.53 billion in the fourth quarter of fiscal 2020.

Latest articles

Marathon Petroleum (MPC) stock has been tumbling in Q3, driven by geopolitical tensions, oil price uncertainty, and weaker refining conditions.

This week, AT&T CEO Randall Stephenson noted that AT&T (T) is on track to reduce its leverage multiple to about 2.5x by the end of this year.

Jeff Bezos announced that Amazon had placed an order of 100,000 electric delivery vans from Michigan-based startup Rivian.

Bad news on the trade war front appears to have led to a fall in the broader US equity markets today. Cannabis ETFs were also trading in the red.

Energy Transfer (ET) stock has recovered in the last two trading sessions after investors hammered it on its plans to acquire SemGroup (SEMG).

Software-as-a-service company Datadog (DDOG) made a smashing debut on Wall Street yesterday. After its IPO, DDOG's shares surged 40% in intraday trading.